Sign in
TerminatedPhase 2

Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma

Key facts

Who runs it
Second Affiliated Hospital, Zhejiang University, School of Medicine
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
16 people enrolled
Started
15 Jan 2021
Ended
4 Aug 2025
Type of study
Interventional
Treatments tested
  • Anlotinib
Record updated
18 November 2026
Why it stopped
The trial was terminated early because free anlotinib was no longer available for newly enrolled patients.

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (14)Hide the full registry criteria

Who can take part

  • Aged 18-70 years,
  • Histologically proven diagnosis of glioblastoma (WHO grade IV),
  • Have received standard STUPP treatment plan,
  • Gross resection or partial resection of the tumor (confirmed by MRI)> 50%,
  • The pathological tissue specimens are detected as MGMT unmethylated,6.Karnofsky performance status ≥ 60,
  • No previous radiotherapy, chemotherapy, immunotherapy or biotherapy 7.Adequate bone marrow function: Hemoglobin ≥ 100g/L,Platelets ≥ 80×109/L,Absolute neutrophil count (ANC) ≥ 1.5×109/L; 8.Adequate renal function: Serum creatinine ≤ 1.25 x UNL (upper normal limit) or creatinine clearance ≥ 60 ml/min 9.Adequate hepatic function: serum bilirubin ≤ 1.5 x UNL, AST and ALT ≤ 2.5 x UNL,ALP≤5x UNL 10.For females of child-bearing potential, negative serum pregnancy test within 14 days prior to registration. Women of childbearing potential and male participants must practice adequate contraception during participation in the study and within 8 weeks after the last administration of the drug 11.Able to provide written informed consent

Who cannot take part

  • Have received radiotherapy, chemotherapy or other anti-tumor drugs for the disease before surgery
  • Previously received radiation therapy for the head and neck cancer
  • Have received any antibody treatment before
  • Recurrent or multiple malignant gliomas
  • Contraindication of radiotherapy and chemotherapy defined as follows: Acute bacterial or fungal infection,Unstable angina and/or congestive heart failure within the last 6 months,co-morbidity with immunosuppressive therapy
  • Evidence of bleeding diathesis or coagulopathy
  • Prior invasive malignancy (except for non-melanomatous skin cancer or carcinoma in situ of cervix)
  • Subtentorial glioblastoma or metastatic lesions outside the skull

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to test the efficacy and safety of Anlotinib in combination with STUPP regimen for MGMT promoter nonmethylated glioblastoma.

The group in the trial

  • ExperimentalTreatment being tested

    For MGMT unmethylated glioblastoma, during temozolomide adjuvant, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14)

    Treatment: Anlotinib

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Anlotinib Combined With STUPP Protocol as First-line Regimen for MGMT Nonmethylated Glioblastoma: a Multicenter, Open-label, Single-arm, Phase II Clinical Trial
Record updated
18 November 2026